Home Companies Catalysts Deep Dives
MARITIME-2 PHASE3 ACTIVE
Drug: MariTide · AMGN
Study Design
DesignRandomized, double-blind, placebo-controlled
BlindingDouble-blind
Duration72 weeks
NCTNCT06858878
Treatment Arms
MariTide Dose 1 Target dose 1 SC Q4W (8-week escalation)
MariTide Dose 2 Target dose 2 SC Q4W (8-week escalation)
MariTide Dose 3 Target dose 3 SC Q4W (8-week escalation)
Placebo Placebo SC
Primary Endpoints
[{"id":"wl-72wk","name":"% change in body weight at Week 72","type":"PRIMARY","unit":"%","results":[],"timepoint":"Week 72","description":"Weight loss in obesity patients WITH T2D. Phase 2 Cohort B showed -12.3% ITT at 52wk — 72wk could reach -15%+."}]
Assessment
FULLY ENROLLED as of Q4 2025. Readout expected early 2027. Dual-label (obesity + T2D) is essential for competitive positioning vs Mounjaro/Zepbound. Source: ClinicalTrials.gov NCT06858878, Amgen Q4 2025 earnings
Background & Context
Pivotal trial in obesity with T2D — critical for dual-label strategy
Data from Supabase · Updated 2026-03-24